Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Alnylam Pharmaceuticals is the leading commercial-stage RNAi therapeutics company with four approved products targeting rare genetic diseases: ONPATTRO (hereditary ATTR amyloidosis), GIVLAARI (acute hepatic porphyria), OXLUMO (primary hyperoxaluria type 1), and AMVUTTRA (hereditary ATTR amyloidosis). The company pioneered RNA interference technology that silences disease-causing genes in the liver, establishing a dominant IP position with over 200 patents and exclusive delivery platform technology. Revenue growth is driven by AMVUTTRA uptake (launched 2022, rapidly gaining share from ONPATTRO) and geographic expansion in Europe and Asia, with the company achieving profitability in 2024 after two decades of R&D investment.
Alnylam operates a high-margin rare disease model with annual treatment costs ranging $400,000-$600,000 per patient. Revenue scales through patient identification (genetic testing partnerships), physician education in specialized centers (20-30 key treatment sites per indication), and lifetime therapy duration (chronic progressive diseases). Pricing power derives from lack of alternatives for validated genetic targets, orphan drug exclusivity (7 years US), and payer willingness to cover due to demonstrable clinical benefit in severe diseases. The company's GalNAc conjugate delivery platform enables subcutaneous self-administration, reducing healthcare system costs versus IV infusions and improving patient compliance. Gross margins exceed 80% due to relatively low manufacturing costs for synthetic oligonucleotides versus biologics, with operating leverage improving as the commercial infrastructure supports multiple products without proportional SG&A increases.
AMVUTTRA quarterly patient additions and market share gains versus ONPATTRO (target 3,000+ patients by 2027 from estimated 1,800 currently)
Phase 3 clinical trial readouts for pipeline assets, particularly vutrisiran (HELIOS-B cardiovascular trial results expected mid-2026) and zilebesiran (hypertension program with potential $5B+ peak sales)
FDA approval decisions and label expansions (AMVUTTRA cardiovascular indication could double addressable market to 150,000+ patients globally)
Partnership announcements or M&A activity given the company's platform value and $44B market cap making it an acquisition target for large pharma seeking rare disease/genetic medicine capabilities
Gene editing technologies (CRISPR, base editing) could provide one-time curative alternatives to chronic RNAi therapy by 2028-2030, particularly for liver-targeted genetic diseases where Alnylam focuses. Intellia and Verve Therapeutics are advancing competing programs for ATTR amyloidosis and cardiovascular targets.
Pricing pressure from IRA drug price negotiations beginning 2026 for Medicare, though rare disease orphan drugs are partially protected. International reference pricing could compress ex-US margins if European HTA bodies demand 30-40% discounts from US list prices.
Platform competition from Arrowhead Pharmaceuticals and Silence Therapeutics developing alternative RNAi delivery technologies that avoid Alnylam's GalNAc patents, potentially eroding IP moat by 2027-2028 as key composition-of-matter patents expire.
Ionis Pharmaceuticals' antisense oligonucleotide platform targets overlapping indications (ATTR, cardiovascular) with different mechanism but similar liver-targeting approach. Ionis has 50+ partnered programs providing diversification advantage.
BridgeBio's acoramidis (oral small molecule for ATTR cardiomyopathy) showed positive Phase 3 data in 2024 and could capture 20-30% of the cardiovascular ATTR market with more convenient oral dosing versus subcutaneous injection, though efficacy appears modestly inferior to AMVUTTRA.
Convertible debt burden of $1.5B+ (2027-2029 maturities) will require refinancing or conversion, potentially diluting equity by 8-12% if stock price remains below conversion prices ($180-220 range). Current stock price around $250 suggests in-the-money conversion likely.
Cash burn risk if pipeline programs fail and revenue growth disappoints - company currently generates $500M operating cash flow but invests $800M+ in R&D. Two consecutive Phase 3 failures could force capital raise or partnership deals on unfavorable terms.
low - Rare disease treatments for life-threatening genetic conditions exhibit minimal GDP correlation. Patients do not defer therapy during recessions as diseases are progressive and fatal without treatment. However, diagnostic rates may slow modestly during economic stress if genetic testing budgets are constrained at hospitals. Estimated <5% revenue sensitivity to GDP fluctuations.
Rising rates create moderate valuation pressure as biotech stocks trade on long-duration cash flows (peak sales projected 2030-2035). Higher discount rates compress NPV of pipeline assets by 15-25% when 10-year yields rise 100bps. Operationally, Alnylam holds $2.5B+ cash with minimal debt refinancing risk (debt is convertible notes due 2027-2029), so financing costs are not a material headwind. The company's recent profitability reduces dependence on capital markets versus pre-revenue biotechs.
Minimal direct exposure. Payer mix is heavily weighted toward commercial insurance (60-65%) and government programs (Medicare/Medicaid 25-30%), with <5% patient assistance. Rare disease drugs maintain >95% prior authorization approval rates due to clear medical necessity. Credit tightening could theoretically impact hospital budgets for genetic testing programs that identify patients, but effect is negligible given the small absolute dollar amounts ($500-1000 per test).
growth - Institutional investors seeking exposure to rare disease commercial execution and platform technology with 65% revenue CAGR and recent profitability inflection. The stock appeals to biotech specialists, healthcare-focused hedge funds, and crossover growth managers given the transition from clinical-stage risk to commercial-stage predictability. Momentum investors have rotated out following the 28% three-month decline, creating potential entry point for fundamental long-term holders. Limited dividend appeal (no payout) and minimal value investor interest given 12x P/S ratio.
high - Biotech sector volatility amplified by binary clinical trial events, FDA decisions, and interest rate sensitivity. Estimated beta 1.3-1.5 versus S&P 500. Stock exhibits 30-40% intraday moves on Phase 3 data releases and 15-20% swings on earnings beats/misses. Recent 28% three-month decline reflects sector-wide biotech weakness and profit-taking after strong 2024-2025 run, not company-specific fundamentals. Options market implies 35-40% annualized volatility.
